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ABSTRACT
Objective To develop and validate a prediction model 
of mortality in patients with COVID-19 attending hospital 
emergency rooms.
Design Multivariable prognostic prediction model.
Setting 127 Spanish hospitals.
Participants Derivation (DC) and external validation 
(VC) cohorts were obtained from multicentre and single- 
centre databases, including 4035 and 2126 patients with 
confirmed COVID-19, respectively.
Interventions Prognostic variables were identified 
using multivariable logistic regression.
Main outcome measures 30- day mortality.
Results Patients’ characteristics in the DC and VC 
were median age 70 and 61 years, male sex 61.0% 
and 47.9%, median time from onset of symptoms to 
admission 5 and 8 days, and 30- day mortality 26.6% 
and 15.5%, respectively. Age, low age- adjusted 
saturation of oxygen, neutrophil- to- lymphocyte ratio, 
estimated glomerular filtration rate by the Chronic 
Kidney Disease Epidemiology Collaboration (CKD- 
EPI) equation, dyspnoea and sex were the strongest 
predictors of mortality. Calibration and discrimination 
were satisfactory with an area under the receiver 
operating characteristic curve with a 95% CI for 
prediction of 30- day mortality of 0.822 (0.806–0.837) in 
the DC and 0.845 (0.819–0.870) in the VC. A simplified 
score system ranging from 0 to 30 to predict 30- day 
mortality was also developed. The risk was considered to 
be low with 0–2 points (0%–2.1%), moderate with 3–5 
(4.7%–6.3%), high with 6–8 (10.6%–19.5%) and very 
high with 9–30 (27.7%–100%).
Conclusions A simple prediction score, based on 
readily available clinical and laboratory data, provides a 
useful tool to predict 30- day mortality probability with 
a high degree of accuracy among hospitalised patients 
with COVID-19.
INTRODUCTION
The clinical spectrum of the novel SARS- CoV-2 
associated COVID-19 varies broadly, from asymp-
tomatic disease to pneumonia and life- threatening 
complications, including acute respiratory distress 
syndrome, multisystem organ failure and death.1–4
The main poor prognostic factor identified in 
different series of COVID-19 is advanced age.3 5 6 
Other factors that have been associated with poor 
outcomes include male gender, several comorbid-
ities, lymphocyte counts, high concentrations of 
different inflammatory or coagulation markers, 
serum levels of different cytokines and features 
derived from imaging studies.5 7–10
Prediction prognostic models are developed to 
aid healthcare providers in estimating the prob-
ability or risk that a specific event will occur, to 
inform their decision- making.11 Prediction models 
can be based on regression or machine learning.12 
In a recent systematic review and critical appraisal 
of prediction models for diagnosis and prognosis 
of COVID-19, 50 prognostic models were identi-
fied; 23 estimated mortality risk, 8 aimed to predict 
severe disease or critical illness and the remaining 
19 assessed other outcomes.13 The majority of the 
models included in the review used clinical and 
laboratory data from Chinese patients. All models 
were considered to have a high risk of bias due 
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to a combination of poor reporting and poor methodological 
conduct for participant selection, predictor description and 
statistical methods, and none were recommended for clinical 
use.13 14 Eight additional studies of prognostic prediction models 
for COVID-19, including predominantly participants from 
China, have been published.15–22 Outcomes included mortality 
in five studies16 17 19–21 and severe disease or critical illness in 
three.15 18 22 The model performance was good across all studies, 
although the same methodological limitations found in the meta- 
analysis also applied.
The development of a high- quality clinical predictive model of 
death to stratify patients into risk groups is essential for improving 
the management of patients with severe COVID-19 and evalu-
ating therapeutic interventions' efficacy. Our study’s objective was 
to develop and validate a prediction score to estimate the proba-
bility of 30- day mortality in patients with severe COVID-19.
METHODS
The predictive model’s development followed the recommen-
dations stated in the Transparent Reporting of a multivari-
able prediction model for Individual Prognosis or Diagnosis 
(TRIPOD) Initiative11 23 (see online supplemental appendix table 
1).






P valueMissing values Valid cases Value Missing values Valid cases Value
Demographics
  Median age (IQR)—years 4 4031 70 (56–80) 0 2202 61 (46–78) <0.001
  Male sex—N (%) 48 3987 2433 (61.0) 1 2201 1054 (47.9)) <0.001
Comorbidity
  Current smoker—N (%) 1.118 2917 197 (6.8) 97 2105 156 (7.4) <0.001
  Hypertension—N (%) 25 4010 2052 (51.2) 17 2185 907 (41.5) <0.001
  Diabetes—N (%) 33 4002 871 (21.8) 16 2186 378 (17.3) <0.001
  Chronic kidney disease—N (%) 35 4000 199 (5.0) 2039 163 76 (46.6) <0.001
  Obesity (BMI>30)—N (%) 429 3606 497 (13.8) 61 2141 233 (10.9) 0.001
  Chronic inflammatory disease—N (%) 38 3997 231 (5.8) 0 2202 255 (11.6) <0.001
  HIV/AIDS—N (%) 73 3962 26 (0.7) 20 2182 13 (0.6) <0.001
Disease chronology
  Δt onset of symptoms to admission, days—
median (IQR)
462 3573 5 (2–7) 939 1263 8 (5–11) <0.001
Symptoms and signs <0.001
  History of fever—N (%) 35 4000 3240 (81.0) 35 2167 1568 (72.4) <0.001
  Cough—N (%) 51 3984 2862 (71.8) 36 2166 1098 (50.7) <0.001
  Malaise—N (%) 121 3914 2505 (64.0) 38 2164 907 (41.9) <0.001
  Dyspnoea—N (%) 55 3980 1953 (49.1) 37 2165 1098 (50.7) <0.001
  Myalgia/Arthralgia—N (%) 226 3809 947 (24,9) 2160 588 (27.2) 0.045
  Sputum production—N (%) 72 3963 956 (24.1) 61 2141 311 (14.5) <0.001
  Vomiting/Nausea—N (%) 111 3924 488 (12.4) 0 2202 295 (13.4) <0.001
  Diarrhoea—N (%) 123 3912 471 (12.0) 37 2165 482 (22.3) <0.001
Radiology
  Lung infiltrates on admission—N (%) 165 3870 3002 (77.6) 8 2194 1559 (71,1) <0.001
Oxygenation
  Age adjusted low SaO2—N (%) 490 3545 942 (26.6) 423 1779 344 (19.3) <0.001
Laboratory parameter
  Neutrophil- to- lymphocyte ratio—Median (IQR) 90 3945 4.5 (2.7–7.7) 636 1566 4.7 (2.9–8.0) 0.013
  Platelets—number×1012 L—Median (IQR) 75 3960 178 (139–226) 636 1566 218 (169–285) <0.001
  D- dimer—ng/mL—Median (IQR) 2472 1563 580 (339–1040) 1325 877 736 (418–1374) <0.001
  eGFR—mL/min/1.73 m2 (CKD- EPI)—Median (IQR) 140 3895 78.4 (56.5–93.6) 645 1557 88.9 (71.5–103.1) <0.001
  ALT—U/L—Median (IQR) 796 3239 26 (18–41) 719 1483 31 (20–48) <0.001
  Serum albumin—g/dL—Median (IQR) 2624 1411 3.5 (3.2–3.9) 1071 1131 4.3 (3.9–4.5) <0.001
  Lactate dehydrogenase—U/L—Median (IQR) 1457 2578 290 (224–403) 967 1235 320 (254–404) <0.001
  C reactive protein—mg/L—Median (IQR) 358 3677 54 (20–116) 782 1420 75 (25–151) <0.001
ALT, alanine aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; SaO2, saturation of oxygen; Δt, time interval.
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Source of data
The data source was the databases of two large retrospective 
cohorts of hospitalised patients with COVID-19 in Spain in 
2020. The derivation cohort (DC) was the COVID-19@Spain, 
a multicentre cohort of patients hospitalised from 2 February to 
17 March, with 17 April as the follow- up censoring date, spon-
sored by the Spanish Society of Infectious Diseases and Clinical 
Microbiology (SEIMC), and registered in  ClinicalTrials. gov 
(NCT04355871).24 The external validation was COVID-19@
HULP, a large single- centre cohort of patients admitted to La 
Paz University Hospital in Madrid (Spain) from 25 February 
(the first case admitted) to 19 April; and registered in the Euro-
pean Union Electronic Register of Post- Authorisation Studies 
(EUPAS34331).25
Table 2 Unadjusted association between candidate predictor variables and outcome in the derivation cohort (N=4035)
Characteristic Number/with data (%)
Death by day 30 OR
(95% CI) P valueYes No
Sex <0.001
  Female 1554/3987 341 1213 1
  Male 2433/3987 721 1712 1.5 (1.29 to 1.74)
Age (years) <0.001
  <=40 302/4031 (7.5) 9 293 1
  40–49 374/4031 (9.3) 16 358 1.45 (0.63 to 3.34)
  50–54 266/4031 (6.6) 19 247 2.50 (1.11 to 5.63)
  55–59 279/4031 (6.9) 38 241 5.13 (2.43 to 10.8)
  60–64 356/4031 (8.8) 53 303 5.69 (2.76 to 11.7)
  65–69 401/4031 (9.9) 78 323 7.86 (3.87 to 15.0)
  70–74 522/4031 (12.9) 123 399 10.0 (5.02 to 20.1)
  75–79 521/4031 (12.9) 201 320 20.4 (10.3 to 40.6)
  80–84 410/4031 (10.2) 196 214 29.8 (14.9 to 59.5)
  85–89 379/4031 (9.4) 200 179 36.4 (18.3 to 72.8)
  >=90 221/4031 (5.5) 140 81 56.3 (27.5 to 115)
Hypertension 2052/4010 (51.2) 764 1288 3.22 (2.76 to 3.74) <0.001
Obesity 497/3606 (13.8) 169 328 1.57 (1.29 to 1.93) <0.001
Liver cirrhosis 54/3998 (1.4) 23 31 2.08 (1.21 to 3.58) 0.008
Chronic neurological disorder 373/4002 (9.3) 161 212 2.31 (1.85 to 2.87) <0.001
Neoplasm (active) 352/4035 (8.7) 152 200 2.28 (1.82 to 2.85) <0.001
Dementia 315/3979 (7.9) 184 131 4.52 (3.57 to 5.73) <0.001
Myalgia/Arthralgia 947/3809 (24.9) 155 792 0.49 (0.40 to 0.59) <0.001
Cough 2862/3984 (71.8) 688 2174 0.68 (0.59 to 0.79) <0.001
Dyspnoea 1953/3980 (49.1) 668 1285 2.19 (1.89 to 2.53) <0.001
Altered consciousness 450/3931 (11.4) 220 230 3.15 (2.58 to 3.86) <0.001
White cell count—cells/×109/L <0.001
  <=4000 666/3971 132 534 1
  4000–12 000 2993/3971 778 2215 1.42 (1.15 to 1.75)
  >12 000 312/3971 151 161 3.79 (2.83 to 5.08)
Neutrophil- to- lymphocyte ratio <0.001
  <3.22 1316/3945 207 1109 1
  3.22–6.33 1314/3945 298 1016 1.57 (1.29 to 1.91)
  >6.33 1315/3945 547 768 3.82 (3.17 to 4.59)
eGFR—mL/min/1.73 m2 (CKD- EPI) <0.001
  >=60 2786/3895 (71.5) 512 2274 1
  30–59 844/3895 (21.7) 379 465 3.62 (3.07 to 4.27)
  <30 265/3895 (6.8) 153 112 6.07 (4.67 to 7.88)
Low SaO2 (age- adjusted)* 942/3545 (26.6) 413 529 3.44 (2.93 to 4.05) <0.001
INR>1.1 1503/3301 (45.5) 524 979 2.20 (1.88 to 2.57) <0.001
CRP>5 μg/L 3378/3677 939 2439 3.21 (2.21 to 4.67) <0.001
*≤90% for patients aged >50 years and ≤93% for patients aged ≤50 years.
CKD- EPI, Chronic Kidney Disease Epidemiology Collaboration equation; CRP, C reactive protein; INR, international normalised ratio; SaO2, saturation of oxygen.
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Participants
The DC included the first consecutive 4035 patients with 
COVID-19 admitted to 127 hospitals distributed across all 
regions in Spain. The external validation cohort (VC) included 
2126 of the 2226 patients from COVID-19@HULP after the 
exclusion of the 100 patients contributing to COVID-19@
Spain. The eligibility criteria in the DC and external VC were 
hospital admission due to COVID-19 confirmed with real- time 
PCR for SARS- CoV-2. No age limit was required in the DC, 
whereas an age of 18 years or older was an eligibility criterion 
in the external VC. The DC and VC were identical in terms of 
setting and definitions for outcomes and predictors. Besides, 
data in both cohorts were collected using the same modified 
version of the case report form (CRF) of the WHO–International 
Severe Acute Respiratory and Emerging Infections Consortium 
(ISARIC) Core CRF.26
Outcome
The outcome was 30- day all- cause mortality, measured from the 
day of hospital admission. Patients that were discharged alive 
before 30 days after admission were assumed to have survived 
for at least 30 days.
Predictors
Predictors were preselected among the 17 baseline variables, 
recorded at hospital admission, independently associated with 
death in the COVID-19@Spain cohort by multivariable Cox 
regression analyses.24 These variables were distributed in the 
following five clusters: (1) demographics, age in years and sex 
at birth; (2) comorbidities defined as diagnoses included in the 
medical record such as hypertension, obesity (body mass index 
>30), liver cirrhosis, chronic neurological disorder, active 
neoplasia (solid or haematologic) and dementia; (3) signs or 
symptoms, including dyspnoea and confusion; (4) low age- 
adjusted capillary oxygen saturation (SaO2) on room air, defined 
as ≤90% for patients aged >50 years and ≤93% for patients 
Table 3 Predictive model for 30- day mortality at presentation in hospitalised patients with COVID-19
Predictor variable Coefficient SE OR (95% CI) p>z
Age <0.001
  40–49 years 0.082 0.446 1.09 (0.45 to 2.6)
  50–54 years 0.471 0.448 1.60 (0.67 to 3.86)
  55–59 years 1.058 0.412 2.88 (1.28 to 6.46)
  60–64 years 1.228 0.394 3.42 (1.58 to 7.4)
  65–69 years 1.655 0.381 5.23 (2.48 to 11.04)
  70–74 years 1.772 0.372 5.88 (2.84 to 12.21)
  75–79 years 2.268 0.373 9.66 (4.65 to 20.07)
  80–84 years 2.695 0.377 14.8 (7.08 to 30.96)
  85–89 years 2.803 0.379 16.49 (7.84 to 34.67)
  >90 years 3.103 0.397 22.26 (10.22 to 48.48)
Low age adjusted SaO2 0.875 0.102 2.40 (1.97 to 2.93) <0.001
Neutrophil- to- lymphocyte ratio <0.001
  3.22–6.33 0.173 0.123 1.19 (0.93 to 1.51)
  >6.33 0.657 0.119 1.93 (1.53 to 2.44)
eGFR (CKD- EPI) <0.001
  30–59 mL/min/1.73 m2 0.498 0.109 1.65 (1.33 to 2.04)
  <30 mL/min/1.73 m2 1.093 0.176 2.98 (2.11 to 4.21)
Dyspnoea 0.414 0.097 1.51 (1.25 to 1.83) <0.001
Male sex 0.466 0.098 1.59 (1.31 to 1.93) <0.001
Intercept −4.266 0.360
CKD- PI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate calculated by the CKD- EPI; SaO2, oxygen saturation.
Figure 1 Calibration of the final prognostic model in the derivation 
cohort. Observed versus predicted risk of 30- day mortality, with 
estimates of the calibration slope and intercept (Hosmer- Lemeshow 
test=11.21, p=0.1902 vs p<0.05).
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aged ≤50 years27; (5) tests results, including white cell count, 
neutrophil- to- lymphocyte ratio, platelet count, international 
normalised ratio (INR), estimated glomerular filtration rate 
(eGFR) measured by the Chronic Kidney Disease Epidemiology 
Collaboration (CKD- EPI) equation28 and serum concentrations 
of C reactive protein.
Statistical analysis methods
We followed recent recommendations to calculate the minimum 
sample size required for prediction model development.29 We 
carried out a complete- case analysis (primary analysis) and two 
sensitivity analyses. In the first sensitivity analysis, we included 
all patients and missing values for predictors were considered as 
a separate category (missing indicator method). In the second 
sensitivity analysis, we also included all patients and missing 
values for predictors were left blank (equivalent to the lowest 
risk situation). No missing values for outcomes occurred in the 
DC or the external VC.
Continuous variables were categorised for the analysis. As 
mortality from COVID-19 among hospitalised patients is highly 
correlated with age, this variable was divided into 11 levels: 
<40 years that was the reference category and after that into 
11 5- year to 10- year intervals up to ≥90 years that was the last 
category. The neutrophil- to- lymphocyte ratio was categorised 
into tertiles: <3.22, which was the reference category, 3.22 to 
6.33, and >6.33. The eGFR in mL/min/1.73 m2 was grouped 
before the analysis into three categories: >60 (normal to mildly 
decreased eGFR), 30–59 (moderately to severely decreased 
eGFR) and <30 (severely decreased eGFR).
We used univariable and multivariable logistic regression in 
the derivation dataset to estimate the coefficients of each poten-
tial predictor of 30- day overall mortality. We fitted the final 
model by choosing predictors based on the strength of their 
unadjusted association with death. The model started with the 
predictor with the highest area under the receiver operating 
characteristics (AUROC) to predict 30- day mortality. Subse-
quently, the rest of the variables were introduced one by one, 
creating all the possible models of two independent variables, 
and the combination of higher AUROC was chosen. This process 
was repeated to form models of 3, 4 and more variables, always 
choosing the combination with the highest AUROC. The process 
stopped when the inclusion of a new variable in the model meant 
an increase lower than 0.005 unit in the AUROC.
We assessed the predictive performance of the model by exam-
ining measures of calibration and discrimination. We developed a 
calibration plot with estimates of the calibration slope and inter-
cept. Calibration was also assessed using the Hosmer- Lemeshow 
test. Discrimination was examined by calculating its AUROC 
with the 95% CI. We carried out internal validation through a 
bootstrap with 1000 random samples with replacement to esti-
mate the model optimism and shrinkage factor.
The logistic regression model’s coefficients were converted 
to a simplified score to facilitate its application in clinical prac-
tice. The score was developed, dividing each coefficient by the 
coefficient with the lowest value and rounding to an integer. 
Risk groups were created using the 30- day probability of death 
according to the simplified score. The sensitivity, specificity, 
positive and negative predictive values, and likelihood ratios 
were calculated for different scores.
The statistical analyses were performed using Stata software 
(V.15.0; Stata Corporation, College Station, Texas, USA).
RESULTS
Participants
The developing cohort included 4035 patients, of which 1074 
(26.6%) died and 2961 were alive within 30 days of hospital 
admission. The cohort size was more than twice the required 
for developing a clinical prognostic model (online supplemental 
appendix figure 1). The external VC included 2202 patients, 
341 (15.5%) died and 1861 were alive within 30 days of hospital 
admission. The median time to death since hospital admission 
was 10 (IQR 6–16) days in the -DC and 5 (IQR 3–10) days in 
the VC.
The characteristics of the participants, including demo-
graphics, presenting signs and symptoms, presence of lung 
infiltrates on chest radiograph, oxygenation and laboratory 
parameters, are shown in table 1. Patients in the DC were, on 
average, 9 years older, and more frequently, males than patients 
in the external VC. Statistically significant differences between 
the cohorts were found in all the analysed variables.
In the DC, targeted viral agents were administered to 82.0% 
of patients, including lopinavir/ritonavir (LPV/r) (70.4%), 
hydroxychloroquine (65.5%) and subcutaneous interferon- beta 
(29.2%), usually in combination with LPV/r. In the external VC, 
targeted viral agents were administered to 65.3% of patients. 
The most frequent combination was hydroxychloroquine plus 
azithromycin (31.7%), followed by hydroxychloroquine alone. 
Host- targeted agents in the DC included systemic corticosteroids 
Figure 2 (A) Simple scoring system to predict 30- day mortality 
on presentation in hospitalised patients with COVID-19. (B) 30- day 
mortality probability according to the total risk score in the derivation 
cohort and the external validation cohort. CKD–EPI, Chronic Kidney 
Disease Epidemiology Collaboration equation; eGFR, estimated 
glomerular filtration rate; SaO2, oxygen saturation.
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in 28.0% patients and tocilizumab in 9.4% patients. In the VC, 
corticosteroids and tocilizumab were administered to 13.3% and 
2.3% patients, respectively.
Model development and performance
The number of participants in the DC without missing values for 
each predictor, the number of outcomes per predictor and the 
unadjusted associations between predictors and outcomes are 
shown in table 2.
The final prediction model generated without recoding missing 
values (3358 participants) is shown in table 3. The variables used 
in the model to generate the score were those in table 2. The 
model started with the variable age since it was the one with the 
highest predictive capacity for death at 30 days (AUROC (95% 
CI) 0.768 (0.753 to 0.784)). The final input sequence of the 
variables to the model, following the procedure described in the 
Methods section, was age, low age- adjusted SaO2, neutrophil- 
to- lymphocyte ratio, eGFR by the CKD- EPI equation, dyspnoea 
and sex.
The predicted probability of 30- day mortality was determined 
by the following equation:
P death at day 30 = 1 / (1+exp (- b)),
where b=0 (if age <40)+0.082 (if age 40–49)+0.471 (if age 
50–54)+1.058 (if age 55–59)+1.228 (if age 60–64)+1.655 (if 
age 65–69)+1.771 (if age 70–74)+2.268 (if age 75–79)+2.695 
(if age 80–84)+2.803 (if age 85–89)+3.103 (if age>=90)+0.875 
(if low age- adjusted SaO2)+0.173 (if neutrophil- to- lymphocyte 
ratio 3.22–6.33)+0.657 (if neutrophil- to- lymphocyte ratio 
>6.33)+0.498 (if eGFR 30–59)+1.093 (eGFR <30)+0.414 (if 
dyspnoea)+0.466 (if male sex)−4.266.
Table 4 Prediction of 30- day mortality on presentation in hospitalised patients with COVID-19 according to the point score in the derivation cohort 
and in the external validation cohort
Risk score





Yes No Yes No
N % N % N % N %
0 48 1 2.1 47 97.9 20 0 0.0 20 100
1 139 0 0.0 139 100 68 0 0.0 68 100
2 193 3 1.6 190 98.4 104 0 0.0 104 100
3 215 10 4.7 205 95.3 103 0 0.0 103 100
4 230 11 4.8 219 95.2 109 1 0.9 108 99.1
5 254 16 6.3 238 93.7 107 4 3.7 103 96.3
6 235 25 10.6 210 89.4 112 5 4.5 107 95.5
7 237 32 13.5 205 86.5 80 8 10.0 72 90.0
8 200 39 19.5 161 80.5 63 8 12.7 55 87.3
9 191 53 27.7 138 72.3 42 8 19.0 34 81.0
10 136 39 28.7 97 71.3 45 12 26.7 33 73.3
11 133 45 33.8 88 66.2 45 11 24.4 34 75.6
12 94 36 38.3 58 61.7 26 5 19.2 21 80.8
13 91 40 44.0 51 56.0 18 7 38.9 11 61.1
14 75 32 42.7 43 57.3 19 5 26.3 14 73.7
15 80 32 40.0 48 60.0 27 9 33.3 18 66.7
16 83 36 43.4 47 56.6 32 10 31.3 22 68.8
17 123 48 39.0 75 61.0 40 14 35.0 26 65.0
18 97 51 52.6 46 47.4 49 16 32.7 33 67.3
19 104 55 52.9 49 47.1 41 13 31.7 28 68.3
20 96 50 52.1 46 47.9 23 9 39.1 14 60.9
21 74 51 68.9 23 31.1 17 6 35.3 11 64.7
22 44 24 54.5 20 45.5 17 7 41.2 10 58.8
23 37 23 62.2 14 37.8 12 4 33.3 8 66.7
24 33 20 60.6 13 39.4 15 8 53.3 7 46.7
25 23 14 60.9 9 39.1 13 5 38.5 8 61.5
26 33 17 51.5 16 48.5 9 4 44.4 5 55.6
27 25 14 56.0 11 44.0 8 6 75.0 2 25.0
28 20 19 95.0 1 5.0 3 1 33.3 2 66.7
29 9 7 77.8 2 22.2 2 2 100 0 0.0
30 6 6 100 0 0.0 0 0 0.0 0 0.0
Total 3358 849 25.3 2509 74.7 1269 188 14.8 1081 85.2
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The final model showed good calibration across the range of 
risk (figure 1), and the goodness- of- fit Hosmer- Lemeshow test 
was 11.21, p=0.1902 vs p<0.05, confirming the calibration 
of the model. Using bootstrapping techniques, an optimism of 
0.006 and a shrinkage factor of 0.968 were estimated. In 600 of 
the samples (60%), the Hosmer- Lemeshow test was significant.
The AUROC (95% CI) of the model for prediction of 30- day 
mortality was 0.822 (0.806 to 0.837) in the DC and 0.845 
(0.819 to 0.870) in the external VC (online supplemental 
appendix table 2).
Simplified score development and performance
The simplified point score (from 0 to 30) resulting from the divi-
sion of the regression coefficients of predictors in the final model 
by the coefficient of age 40–49, which was the lowest value 
among all coefficients, is shown in figure 2A. The prediction of 
30- day mortality on presentation in hospitalised patients with 
COVID-19 according to the point score in the DC and in the 
external VC is shown in table 4.
The AUROC (95% CI) of the simplified score for prediction 
of 30- day mortality was 0.806 (0.790 to 0.821) in the DC and 
0.831 (0.806–0.856) in the external VC (online supplemental 
appendix table 2). The sensitivity, specificity, positive and nega-
tive predictive values, and likelihood ratios for the different 
scores in the DC and external VC are shown in table 5 and 
online supplemental appendix table 3, respectively.
We considered the risk of 30- day mortality as low with 0–2 
points (0%–2.1%), moderate with 3–5 (4.7%–6.3%), high with 
6–8 (10.6%–19.5%) and very high with 9–30 (27.7%–100.0%) 
(figure 2B). Kaplan- Meier survival plots for the different 30- day 
mortality risk categories according to the simplified score in the 
DC and VC are shown in online supplemental appendix figure 2.
Table 5 Simplified score to predict 30- day mortality in hospitalised patients with COVID-19 in the derivation cohort: sensitivity, specificity, 
likelihood ratios and predictive values for the different scores (0–30) in the derivation cohort
Score
Participants
Sen (%) Spe (%) +LR 1/-LR PPV (%) NPV (%)Total
Dying within 30 days
N %
0 48 1 2.1 100 0 1 – 25.3 –
1 139 0 0.0 99.9 1.9 1.018 15.900 25.6 97.9
2 193 3 1.6 99.9 7.4 1.079 62.940 26.7 99.5
3 215 10 4.7 99.5 15.0 1.171 31.810 28.4 98.9
4 230 11 4.8 98.4 23.2 1.280 14.040 30.2 97.6
5 254 16 6.3 97.1 31.9 1.425 10.830 32.5 97.0
6 235 25 10.6 95.2 41.4 1.623 8.567 33.5 96.2
7 237 32 13.5 92.2 49.7 1.835 6.398 38.3 95.
8 200 39 19.5 88.5 57.9 2.102 5.017 41.6 93.7
9 191 53 27.7 83.9 64.3 2.351 3.986 44.3 92.2
10 136 39 28.7 77.6 69.8 2.573 3.120 46.5 90.2
11 133 45 33.8 73.0 73.0 2.776 2.732 48.4 89.0
12 94 36 38.3 67.7 77.2 2.971 2.392 50.1 87.6
13 91 40 44.0 63.5 79.5 3.099 2.178 51.2 86.6
14 75 32 42.7 58.8 81.5 3.185 1.978 51.9 85.4
15 80 32 40.0 55.0 83.3 3.286 1.850 52.6 84.5
16 83 36 43.4 51.2 85.2 3.456 1.747 53.9 83.8
17 123 48 39.0 47.0 87.0 3.628 1.642 55.1 82.9
18 97 51 52.6 41.3 90.0 4.149 1.535 58.4 81.9
19 104 55 52.9 35.3 91.9 4.346 1.421 59.5 80.8
20 96 50 52.1 28.9 93.8 4.671 1.319 61.3 79.6
21 74 51 68.9 23.0 95.7 5.287 1.242 64.1 78.6
22 44 24 54.5 17.0 96.6 4.948 1.163 62.6 77.5
23 37 23 62.2 14.1 97.4 5.373 1.134 64.5 77.0
24 33 20 60.6 11.4 97.9 5.513 1.106 65.1 76.6
25 23 14 60.9 9.1 98.4 5.835 1.083 66.4 76.2
26 33 17 51.5 7.4 98.8 6.206 1.067 67.7 75.9
27 25 14 56.0 5.4 99.4 9.710 1.051 76.7 75.7
28 20 19 95.0 3.8 99.9 31.520 1.038 91.4 75.4
29 9 7 77.8 1.5 99.9 19.210 1.015 86.7 75.0
30 6 6 100 0.7 100 – 1.007 100 74.9
The number of individuals in different risk categories was low (0–2 points; 380 (11.3%)), medium (3–5 points; 699 (20.8%)), high (6–8 points; 672 (20.0%)) and very high (9–30 points; 1607 
(47.9%)).
-LR, negative likelihood ratio; +LR, positive likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; Sen, sensitivity; Spe, specificity.




When we generated the final prediction model recoding missing 
values for predictors as a separate category, the AUROC (95% CI) 
was 0.822 (0.809 to 0.836) in the DC and 0.850 (0.831 to 0.867) in 
the external VC. Likewise, when we applied the same approach to 
the simplified point score, the AUROC (95% CI) was 0.805 (0.791 
to 0.820) in the DC and 0.848 (0.830 to 0.866) in the external VC 
(online supplemental appendix table 2).
Sensitivity analysis 2
When we applied the final prediction model to all patients, and 
missing values for predictors were left blank (equivalent to the 
lowest risk situation), the AUROC (95% CI) was 0.818 (0.805 to 
0.832) in the DC and 0.859 (0.842 to 0.876) in the external VC. 
Likewise, when we applied the same approach to the simplified 
point score, the AUROC (95% CI) was 0.806 (0.791 to 0.820) 
in the DC and 0.849 (0.831 to 0.866) in the external VC (online 
supplemental appendix table 2).
DISCUSSION
The COVID-19 SEIMC score for predicting 30- day mortality 
of patients attending hospital emergency rooms was developed 
and externally validated with two large datasets from patients 
hospitalised with laboratory- confirmed COVID-19 in Spain. 
The predictors were age, low age- adjusted SaO2, neutrophil- to- 
lymphocyte ratio, eGFR by the CKD- EPI equation, dyspnoea 
and sex. The model showed good performance in both the DC 
and the external VC and permitted an easy stratification of 
patients into four risk categories.
Our prediction model uses widely accessible clinical and labo-
ratory data, and its simplicity would allow clinicians to perform 
rapid risk stratification of patients with COVID-19. Of note, our 
model does not take into account comorbidities, which have been 
associated with worse COVID-19 prognosis in descriptive studies 
and included in most prognostic prediction models reported to 
date.13 15–22 In our study, underlying diseases such as hyperten-
sion, obesity, liver cirrhosis, chronic neurological disorder, active 
neoplasia and dementia were independently associated with an 
increased risk of 30- day mortality. However, none of these condi-
tions improved the model’s discrimination capacity and, following 
the principle of parsimony, were discarded.
Once again, our study highlights the extraordinary impact 
of age on COVID-19 mortality, which is, to the best of our 
knowledge, unparalleled in infectious diseases. For example, 
our score would classify a 65- year- old male patient attending 
the emergency room— regardless of the results of the other vari-
ables—as a high- risk category with a 30- day mortality proba-
bility that could reach up to 19.5%. For younger patients, our 
score also shows the importance of basic laboratory parameters. 
A 55- year- old man without dyspnoea, normal SaO2 and normal 
renal function but with a neutrophil- to- lymphocyte ratio higher 
than 6.33 would also be classified as high risk.
At the time of writing, an eight variable mortality score devel-
oped and validated in a UK prospective cohort of 57 824 patients 
admitted to hospital with COVID-19, the 4C Mortality Score, 
has been published.30 Some of the variables included in this 
score, such as respiratory rate, Glasgow Coma Scale score and 
urea, are not available in the COVID-19@Database precluding 
the cross- validation the 4C Mortality Score in our population.
Our study is limited, as is the case with other reported studies, 
by the retrospective capture of data. Another potential limita-
tion is that it was based exclusively on predictors from patients 
attending hospital emergency rooms. However, we believe that 
our score could be applied in primary care settings if capillary 
SaO2 and routine laboratory tests such as blood counts and 
serum creatinine could be determined. Finally, our score was 
derived from hospitalised patients in a single country, raising 
the question about their transportability to other countries, a 
common limitation to all currently described prognostic models 
of COVID-19. We believe that it would be of interest to carry 
out cross- validation between the SEIMC COVID-19 score and 
other scores in a large multinational dataset.
Our study has several strengths. In contrast with the majority of 
prior published prognostic models, ours adhere to the TRIPOD 
statement’s recommendations. Besides, the large sample size and 
the high number of events in the DC minimise the risk of model 
overfitting, a general limitation of previous studies. Our model’s 
strengths also include the calibration, the internal validation 
by bootstrapping rather than by random split of the DC and 
the validation in a large external cohort. Finally, the sensitivity 
analyses exploring different approaches for missing values for 
predictors did not modify the model’s performance, suggesting 
that missing values in both cohorts occurred at random.
The SEIMC COVID-19 score could be a useful triage tool 
enabling quick decision- making for patients with COVID-19. 
For example, patients in the low- risk category are likely suitable 
for outpatient care, whereas hospital admission or intensive or 
high dependency care should be considered for patients in high 
and very high- risk categories. Besides, management in emergency 
department observation units or makeshift medicalised facilities 
could be considered for patients in the moderate risk category. 
Another potential application of the SEIMC COVID-19 score 
is the risk stratification of patients with COVID-19 in observa-
tional studies or clinical trials.
Our study showed that the COVID-19 SEIMC score, a simple 
prediction tool using readily available clinical and laboratory 
data results, could identify the probability of 30- day mortality 
with a high degree of accuracy among patients with COVID-19.
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